ArticleACS omega2019
Copper Nanocluster-Doped Luminescent Hydroxyapatite Nanoparticles for Antibacterial and Antibiofilm Applications.
Article in ACS omega, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 47 citations in OpenAlex.
- Low Percent Copper Doping Limits Bacterial Adhesion on Fluorapatite-Based Bone Scaffolds.Journal of biomedical materials research. Part B, Applied biomaterials · 2026Article
- Copper Nanocluster-Enabled Fluorescent Sensing of Serine: A Strategy for Noninvasive Cancer Biomarker Detection.Journal of fluorescence · 2025Article
- Antibacterial micro/nanomotors: current research progress, challenges, and opportunities.Theranostics · 2024Review
- Size and charge effects of metal nanoclusters on antibacterial mechanisms.Journal of nanobiotechnology · 2023Review
- Biomaterial-assisted tumor therapy: A brief review of hydroxyapatite nanoparticles and its composites used in bone tumors therapy.Frontiers in bioengineering and biotechnology · 2023Review
- From the Physicochemical Characteristic of Novel Hesperetin Hydrazone to Its In Vitro Antimicrobial Aspects.Molecules (Basel, Switzerland) · 2022Article
- Study of Titanium-Silver Monolayer and Multilayer Films for Protective Applications in Biomedical Devices.Molecules (Basel, Switzerland) · 2021Article
- The role of nanohydroxyapatite on the morphological, physical, and biological properties of chitosan nanofibers.Clinical oral investigations · 2021Article
- Chitosan-Coated Surgical Sutures Prevent Adherence and Biofilms of Mixed Microbial Communities.Current microbiology · 2021Article
- Antimicrobial Metal Nanomaterials: From Passive to Stimuli-Activated Applications.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Novel strategies in the field of nanotechnology for the development of suitable multifunctional drug delivery vehicles have been pursued with promising upshots. Luminescent copper nanocluster-doped hydroxyapatite nanoparticles (HAP NPs) were synthesized and applied for the delivery of antibacterial drug kanamycin. The negatively charged doped HAP NPs could electrostatically interact with the positively charged kanamycin. The kanamycin-loaded doped HAP NPs showed pronounced activity in the case of Gram-negative bacteria compared to that in Gram-positive bacteria. Upon interaction with the bacteria, kanamycin could probably generate harmful agents such as hydroxyl radical that leads to bacterial cell damage. After being incorporated with copper nanoclusters (Cu NCs), the doped HAP NPs were applied for the bioimaging of bacterial cells. The biocompatibility of doped HAP NPs was also studied in HeLa cells. As compared to copper nanoclusters, the doped HAP NPs showed excellent biocompatibility even at higher concentrations of copper. The kanamycin-loaded doped HAP NPs were further applied toward
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.